logo

Heron Therapeutics Inc. (HRTX)



Trade HRTX now with
  Date
  Headline
2/24/2021 8:36:16 AM Heron Therapeutics Q4 Net Loss $62.3 Mln Or $0.68/shr Vs. Loss $57.9 Mln Or $0.65/shr Prior Year
1/21/2021 8:41:20 AM Heron Publishes Results From EPOCH 1 Follow-On Study Of HTX-011 In Patients Undergoing Bunionectomy Surgery
1/11/2021 8:44:31 AM Heron Annouunces Progress In Pain Management And CINV Franchises
11/13/2020 8:33:24 AM Heron Therapeutics Resubmits NDA To FDA For HTX-011 For Treatment Of Postoperative Pain
11/5/2020 8:44:14 AM Heron Therapeutics Q3 Loss/Shr $0.64 Vs Loss $0.42 Last Year
9/28/2020 8:36:19 AM Heron Therapeutics Receives EU Authorization For ZYNRELEF For Postoperative Pain
9/16/2020 8:35:58 AM Heron Therapeutics Announces Publication Of Results From EPOCH 2 Follow-On Study
9/8/2020 8:36:26 AM Heron Reports Successful Outcome Of FDA Type A Meeting To Discuss HTX-011 For Management Of Postoperative Pain; Stock Up
7/24/2020 8:32:30 AM Heron Therapeutics Gets Positive CHMP Opinion For ZYNRELEF For The Management Of Postoperative Pain
7/16/2020 8:32:11 AM Heron Therapeutics Begins GUARDS-1 Study, A Phase 2 Clinical Study Evaluating CINVANTI
6/29/2020 8:47:11 AM Heron Therapeutics Gets CRL For HTX-011 For Management Of Postoperative Pain; Stock Plunges
6/4/2020 9:06:22 AM Heron Publishes Results From Study 209, Phase 2b Study Of HTX-011 In Patients Undergoing Total Knee Arthroplasty